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Abstract
Background & Methods: Within the last decade Virus-Like Particles (VLPs) have increasingly received attention
from scientists for their use as a carrier of (peptide) molecules or as scaffold to present epitopes for use in
subunit vaccines. To test the feasibility of Cowpea chlorotic mottle virus (CCMV) particles as a scaffold for epitope
presentation and identify sites for epitope fusion or insertion that would not interfere with virus-like-particle
formation, chimeric CCMV coat protein (CP) gene constructs were engineered, followed by expression in E. coli and
assessment of VLP formation. Various constructs were made encoding a 6x-His-tag, or selected epitopes from Influenza
A virus [IAV] (M2e, HA) or Foot and Mouth Disease Virus [FMDV] (VP1 and 2C). The epitopes were either inserted 1) in
predicted exposed loop structures of the CCMV CP protein, 2) fused to the amino- (N) or carboxyl-terminal (C) ends, or
3) to a N-terminal 24 amino acid (aa) deletion mutant (NΔ24-CP) of the CP protein.
Results: High levels of insoluble protein expression, relative to proteins from the entire cell lysate, were obtained for
CCMV CP and all chimeric derivatives. A straightforward protocol was used that, without the use of purification
columns, successfully enabled CCMV CP protein solubilization, reassembly and subsequent collection of CCMV CP VLPs.
While insertions of His-tag or M2e (7-23 aa) into the predicted external loop structures did abolish VLP formation, high
yields of VLPs were obtained with all fusions of His-tag or various epitopes (13- 27 aa) from IAV and FMDV at the N- or
C-terminal ends of CCMV CP or NΔ24-CP. VLPs derived from CCMV CP still encapsulated RNA, while those from CCMV
CP-chimera containing a negatively charged N-terminal domain had lost this ability. The usefulness and rapid ease of
exploitation of CCMV VLPs for the production of potential subunit vaccines was demonstrated with the synthesis
of chimeric CCMV VLPs containing selected sequences from the GN and GC glycoproteins of the recently
emerged Schmallenberg orthobunyavirus at both termini of the CP protein.
Conclusions: CCMV VLPs can be successfully exploited as scaffold for epitope fusions up to 31 aa at the N- and
C-terminus, and at a N-terminal 24 amino acid (aa) deletion mutant (NΔ24-CP) of the CP protein.
Keywords: CCMV, viral nanoparticles, virus-like particles, VLP, Influenza A virus, Foot and Mouth Disease Virus,
Schmallenberg virus, prokaryote expression system
Backgound
Virus-like particles (VLPs) have become recognized as
ideal biopolymers for various applications within Biona-
notechnology [1], amongst which the production of vac-
cines. Among the various types of vaccines produced,
subunit vaccines receive a particular interest, because
only small antigenic parts of a target pathogen are being
used for immunization. This requires selection of an
immuno-dominant peptide that on its own still induces
a strong immune response capable to (partially) protect
against invasion with the pathogen from which the pep-
tide was derived. A major advantage of a subunit vaccine
is the lack of any risk, i.e. the chance that the vaccine
might elicit a counter response, due to the absence of
the pathogen [2]. Furthermore, a subunit vaccine can in
principle be produced in many different protein expres-
sion systems. However, a drawback of subunit vaccines
is the requirement for multiple doses and the use of ef-
ficient but nontoxic adjuvant formulations to confer
acceptable protection. It is often due to poor immuno-
genicity that has limited the application of these vaccines
[3]. This is most likely caused by improper folding and/or
poor presentation of the antigen subunits to the immune
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system [4]. To enhance the immunogenic properties, anti-
genic subunits are being offered with stronger adjuvants
[5] or more and more displayed on a carrier molecule like
VLPs. Besides being non-infectious, due to the lack of the
viral genome, VLPs resemble authentic viral particles in
their unique structure (and size) and thereby also retain
their ability to induce a strong B cell response, i.e. elicit
neutralizing antibodies in the absence of adjuvants [6–8].
Meanwhile, epitope based-VLP vaccines have been pro-
duced in which only a small antigenic stretch(es) of a tar-
get protein(s) has been incorporated into VLPs and shown
to strongly induce innate and cognate immune responses
and enhancing the generation of antibodies without appli-
cation of adjuvants [7–9].
To date a variety of plant and animal VLPs have been
developed and exploited for peptide/epitope display by
genetic fusion or chemical conjugation [6] which include
Hepatitis B core antigen [10], Papilloma VLPs [11], Bac-
teriophage Qβ [12] and Papaya mosaic VLPs [13, 14]. Ideal
VLP candidates contain at least one tolerable site for the
fusion or insertion of foreign epitopes without any side
effects or toxicity to the recipient [15–17]. VLPs derived
from plant viruses have the additional advantage that ver-
tebrate hosts have never faced an infection with these
pathogens; hence will not neutralize these VLPs once they
are being used for immunization. Thus far several plant
viruses have been studied and a few have been tested in
animal models for their potential vaccine (Table 1). Among
plant viruses, CCMV has not been extensively studied for
these purposes yet, although CCMV VLPs are reported
and have some unique and interesting features. CCMV is a
single-stranded (+)-sense RNA virus and member of the
Bromovirus genus within the family of Bromoviridae. It
consists of spherical particles, approximately 28 nm in
diameter and capsid entirely composed of a single coat
protein (CP) of about 20 kDa [18]. The icosahedral particle
(T = 3) symmetry is composed of 180 copies of the CP
subunit assembled into 12 pentamers and 20 hexamers.
The CP protein consists of 190 aa residues and is com-
posed of an eight β-barrel core (residues 52-176) from
which the amino- (N) (residues 1-51) and carboxyl- (C)
(residues 176-190) termini extend in opposite directions
[19]. The N terminus is highly positively charged and the
first 26 aa project into the capsid interior and contribute
to an electrostatic interaction with viral RNA [20]. The
C-terminus lies tangentially to the capsid structure,
wedging between the N-terminus and β-barrel structure
of the neighbouring CP subunits, and stabilizes dimeric
interactions [21].
One of the highly interesting features of CCMV parti-
cles is that these are able to self-assemble in vitro in a
reversible manner, depending on pH, ionic conditions
and concentration of divalent cations (Ca2+, Mg2+). At
pH above 7.0 CCMV particles disassemble while lowering
the pH below 6, low ionic strength (i = 0.2) [19] and the
additional presence of divalent cations (0.01 M) support
reassembly of CCMV VLPs. When such process is per-
formed in a subtle manner, CCMV VLPs can be manip-
ulated to only swell without disassembly and thereby
allow encapsulation of small molecules into the core of
the particle. In this respect, CCMV VLPs have been
exploited as nanocarriers to encapsulate different types
of cargo molecules i.e. proteins, fluorophore and/or
metal ions [22, 23].
CCMV VLPs have been expressed in several heterologous
expression systems i.e. yeast [24], insect cell (unpublished
Table 1 Plant virus-like particles used as scaffolds for epitope presentation
Virus Particle shape Candidate epitope Reference
Potato leafroll virus (PLRV) Spherical His [44]
Tomato bushy stunt virus (TBSV) Spherical V3 & RTA [45, 46]
Tobacco mosaic virus (TMV) Rod HVR1 [47]
Cowpea mosaic virus (CPMV) Spherical Nlm-1A [48]
Johnson grass mosaic virus (JGMV) Filamentous Peptide A,B,C,D [49]
Alfalfa mosaic virus (AMV) Bacilliform PA-D4s [50]
Physalis mottle virus (PhMV) Spherical 3B1, 3B2, 3AB, 3D,3ABD [51]
Cucumber mosaic virus (CMV) Spherical F & HN [52]
Papaya mosaic virus (PapMV) Filamentous p33-CTL, M2e & HA11 [13, 14, 53]
Cymbidium ringspot virus (CymRSV) Spherical Myc [54]
Potato virus Y (PVY) Filamentous preS1 [55]
Bamboo mosaic virus (BaMV) Filamentous VP2 [56]
Turnip mosaic virus (TuMV) Filamentous VEGFR-3 [57]
Cardamom mosaic virus (CdMV) Filamentous gp41 [58]
Artichoke mottled crinkle virus (AMCV) Spherical 2 F5 [59]
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observation), prokaryotic [19] and analyzed for VLP forma-
tion. High yield of CCMV VLPs and soluble assembled
VLPs were only obtained in yeast (Pichia pastoris) [25] and
Pseudomonas fluorescens [26]. A recent study furthermore
showed that wild type CCMV VLPs generally have a uni-
form distribution and do not show overt toxicity in naïve
and immunized mouse which makes CCMV nanoparticles
very attractive for biomedical applications in terms of their
safety and biocompatibility [24].
Studies on CCMV-based VLPs as an epitope presenta-
tion system, however, are still limited and the informa-
tion as to where fusions and insertions of smaller and/or
larger epitopes can be made to exploit CCMV VLPs as
scaffold for vaccine purposes is not available.
Thus far, only the highly conserved ectodomain of
matrix 2 protein (M2e) of Influenza A virus has been
cross-linked to the surface of CCMV VLPs, or fused to
the N terminus and shown to maintain VLP formation
[27]. Here we present a more extensive study in which
we analyzed four predicted loop structures within CCMV
CP [22] and the N- and C-termini for their potential use
as target sites to insert/fuse epitopes whilst maintaining
VLP formation.
Results
Selection of putative epitope insertion and fusion sites
Potential sites to be tested for fusion and external expo-
sures of epitopes on CCMV VLPs were selected based on
analysis of the CCMV CP crystal structure (Fig. 1). Based
on this, four predicted loops, named βB-βC, βD-βE,
βF-βG- and βH-βI, and the N- and C-termini were se-
lected for insertions respectively fusions (Fig. 2).
Expression and VLP formation of chimeric His-tagged
CCMV CP and NΔ24-CP
To test whether small heterologous sequences could be
inserted or fused, without abrogation of CCMV VLP for-
mation, a first series of CCMV CP chimeras was made
in which a 6xHis-tag was inserted in any of the four
selected and predicted loops, and fused to the N- or
C-terminus (Fig. 2). In addition a CP construct was
generated lacking the first 24 aa (denoted NΔ24-CP),
to be tested on the ability to still fold into VLPs and
potential future exploitation. Constructs were cloned into
pET 28a (Novagen) expression vector, expressed in BL21
cells and subsequently analyzed on sodium dodecylsulfate-
polyacrylamide gels. Polyacrylamide gels were stained with
Coomassie brilliant blue and showed the presence of pro-
tein bands that were absent from BL21 control cells, and
corresponded with the expected sizes of the CCMV CP
chimera and NΔ24-CP. Further analysis revealed that most
of these chimeric proteins ended up in the insoluble
fraction (Fig. 3 and unpublished observation). For this
reason, a protocol was developed to solubilize chimeric
CP proteins from protein aggregates and in vitro reassem-
ble them into VLPs. In a final step highly purified VLPs
were collected from a pellet after ultracentrifugation on
30 % sucrose cushion, as consistently observed when ap-
plied on wt CCMV CP protein (Fig. 3a1, b). Following this
procedure, none of the CCMV CP proteins containing
His-tag insertions in the loops were found ending up in
the pellet fraction except for the CP βF-βG-His protein
(Fig. 3a, panels a2-4). On the other hand, expressed pro-
teins were obtained at concentration range of 36-63 mg/l
in pellets prepared from lysates expressing wt CCMV
CP and CP proteins containing a His-tag at the N- or
Fig. 1 Schematical presentation of a CCMV virion and a coat protein subunit. a CCMV particle according to data from Protein Data Bank (PDB ID: 1ZA7
[http://www.rcsb.org/pdb/home/home.do]) [20] and as visualized by Chimera1.6.2 (http://www.cgl.ucsf.edu/chimera/) [60], showing an icosahedral
asymmetric unit consisting of three identical subunits in the centre, b ribbon diagram of a coat protein subunit B displaying N-terminal end (residues
1-25 are not shown), four β-barrels (βB-βC, βD-βE, βF-βG and βH-βI) and C-terminal end as potential insertion sites. Insertions within the barrels are
shown between the white dashes
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C-terminus of CCMV-CP or at the N-terminus of
NΔ24-CP (Fig. 3b). Since detection of wt CCMV CP
protein in these pellets consistently correlated with the
presence of VLPs, the presence of pellets after sucrose
cushion ultracentrifugation for the other CCMV CP
chimeric proteins was indicative for the formation of
VLPs. Similar to CCMV CP, EM analysis from resus-
pended pellet material indeed confirmed the formation
and presence of VLPs for CCMV CP-chimeric proteins
containing a single 6xHis-tag at its N- or C-terminus
and also when present at both termini simultaneously
(Fig. 4b1-6). For the CCMV CP chimera containing a
6xHis-tag in the βF-βG loop, and for which small amounts
of macro molecular protein complexes (MMPCs) were
found in the pellets after sucrose gradients, no VLPs were
observed. Instead, large aggregates were observed (Fig. 4a1).
Pellets obtained from NΔ24-CP also revealed the presence
of VLPs (Fig. 4b7).
Whereas the CCMV CP construct containing the C-
terminal 6xHis-tag became well expressed (Fig. 3b1),
and the presence of the 6xHis-tag encoding nucleotide
sequence was verified by nucleotide sequence analyses,
the His-tag could not be detected on western immu-
noblots using anti-His serum (Fig. 3b2).
Expression and VLP formation of CCMV CP containing IAV
M2e epitope insertions
To rule out that abrogation of VLP formation in case of
insertion into the loops was not just due to the 6xHis-
tag, a similar set of insertional CCMV CP chimeras was
made but instead of a His-tag now containing the 23 aa
IAV M2e epitope (Fig. 5). Constructs made were cloned
into pET28 and verified by sequence analysis, and after
expression in E.coli further processed for in vitro VLP
reassembly and purification by ultracentrifugation. Whereas
all constructs of CCMV CP containing the M2e epitope
insertion into one of the loops became well expressed
(Fig. 6a), only very low amounts of the βF-βG-M2e(23)
and βH-βI-M2e(23) proteins (Fig. 6a3 and a4) could be
observed in the pellets after sucrose cushion. To test
whether these results were influenced by the size of the
M2e (23 aa) insertion, a range of constructs containing
smaller insertions (7 or 15 aa) were made and analyzed
(Fig. 5). While proteins from the insertional CCMV
chimera βF-βG-M2e(7) and -M2e(15) were detected in
pellets after sucrose cushion (Fig. 6b1 and b3), only very
low amounts were detected for those of βH-βI-M2e(7)
and -M2e(15) (Fig. 6b2 and b4). Western immunoblot
analysis of all CCMV βF-βG loop-insertions showed a
Fig. 2 Schematical diagram of CCMV-CP and NΔ24-CP constructs expressed in E. coli. Six His-tag residues introduced within the predicted loops
(βB-βC-His, βD-βE-His, βF-βG-His and βH-βI-His) were cloned as SpeI-SstI, while for the N- and C-terminal end fusion of the CCMV-CP (His-CP, CP-His
and His-CP-His) and NΔ24-CP (His-NΔ24-CP and His-HA-NΔ24-CP), the 6xHis-tags were introduced by PCR
Hassani-Mehraban et al. BMC Biotechnology  (2015) 15:80 Page 4 of 17
good detection of the His-tag but a weaker one of the
M2e(7) and M2e(15) insertions, likely due to lower re-
activity of the antiserum to a smaller M2e sequence in-
sertion (Fig. 6c). Although the presence of these
proteins in pellets obtained after sucrose cushion ultra-
centrifugation were indicative for MMPC, and consist-
ently observed to correlate with VLP formation of wild
type CCMV CP (Fig. 4b1-3), none of the βF-βG loop
CCMV CP chimera for which also MMPCs were found
in the pellets, did fold into VLPs. Instead, large and
similar aggregates were observed for all βF-βG loop
chimera, as shown for βF-βG-His, βF-βG-M2e(7), βF-
βG-M2e(15) and βF-βG-M2e(23)( Fig. 4a1-4).
Expression and VLP formation of CCMV CP containing IAV
and FMDV epitope N- and C-terminal fusions
To further substantiate the observation that N- and
C-terminal fusions, in contrast to insertions, did not
abolish the reassembly of CCMV CP into VLPs, add-
itional CCMV CP chimera were tested containing dif-
ferent epitopes derived from FMDV (VP1, 2C) and IAV
(M2e, HA) and varying in size, at the N- or C-terminus of
CCMV CP or at the N-terminus of the NΔ24 deletion
mutant (See Methods and Fig. 5).
Clones containing FMDV and IAV epitope sequences
were selected and after being confirmed by sequence ana-
lysis, were expressed in E. coli and analyzed for protein
expression. Upon SDS-PAGE and Western immunoblot
analysis using anti CCMV CP serum, all CCMV CP chi-
meras containing either IAV or FMDV epitopes were well
detected using anti CCMV CP serum (Fig. 6d1 and e1).
Chimeras containing VP1 or M2e fusion proteins add-
itionally were detected with serum from FMDV-infected
animals and anti-M2e serum, respectively (Fig. 6d2
and E2), confirming the presence of those epitopes.
CCMV CP chimera containing FMDV 2C fusions did not
react with the FMDV antiserum. Since the presence of 2C
and HA epitopes was not confirmed serologically (Fig. 6d2),
their presence relied on the confirmation by sequence ana-
lysis of the constructs and the observation that the size of
the chimeric proteins detected using anti-CCMV serum cor-
responded to the expected size of the predicted protein.
After protein samples were subjected to VLP reassembly
and sucrose cushion ultracentrifugation, pellets ob-
tained were resuspended and analyzed by EM. Similar
to the results earlier obtained with His-tag fusions at
the N- or C-termini of CCMV CP, an N-terminal His-tag
fusion to NΔ24-CP did not abolish VLP formation
Fig. 3 Expression of His-tag insertion and terminal fusion CCMV constructs in E. coli. a Cell extracts (CE) and reassembled VLP pellets (RP) collected
through sucrose cushion of CCMV-CP (A1) and CCMP-CP derivatives containing a 6xHis-tag insertion within each of the loop structures (βB-βC-His [A2],
βD-βE-His[A3], βF-βG-His[A4] and βH-βI-His[A5]), were resolved on 15 % SDS-PAGE and stained with Coomassie blue. b Western blots of 6xHis-
tag fusion constructs (His-CP, CP-His, His-CP-His) detected by polyclonal anti-CCMV (B1) and monoclonal anti-His (B2) sera. CCMV-CP and
NΔ24-CP were used as controls for size comparison with the chimeras. A molecular size marker is indicated on the left
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(Fig. 4b8). N-terminal fusions of M2e(23), HA, VP1
and 2C to CCMV CP or NΔ24-CP all resulted in the
formation of VLPs (Fig. 4b9–b17). When His and HA
were combined as a fusion at the N-terminus of CCMV
CP, VLPs were also observed (Fig. 4b10). While fusion of
HA at the C-terminus of CCMV CP, similar to the earlier
observed 6xHis-tag fusion, still maintained VLP forma-
tion, fusions with M2e(23aa) abolished VLP forma-
tion. Instead, tubular-like structures were observed
(Fig. 4b16–b18). During VLP reassembly and EM analysis,
purified CCMV virions and CCMV CP were included as
positive controls (Fig. 4b: b1-b3). Higher resolution of 4
selected VLP samples are shown as examples for CCMV
VLP identification and to provide a more detailed view on
the structure of the VLPs generated (Fig. 4c).
To find out whether epitopes fused at the N or C-
terminus were exposed on the outside of VLPs, immu-
nogold electron microscopy was performed on CCMV
VLPs containing N-terminal and C-terminal His- or
M2e-fusions. However, during several attempts no
immunogold labeling was observed, indicated a possible
internalization of the fusions. While the number of VLPs
observed varied between the different CCMV CP chimera,
most VLPs consistently revealed an average size ranging
(See figure on previous page.)
Fig. 4 Electron micrographs of negatively-stained CCMV-CP/ NΔ24-CP loop insertion and fusion constructs expressed in E. coli. (a) Reassembled
VLP pellet of βF-βG-His (A1), βF-βG-M2e(7) (A2), βF-βG-M2e(15) (A3) and βH-βI-M2e(23) (A4). (b) CCMV virions purified from cowpea plants (B1),
CCMV-CP VLPs (B2), immuno-gold labeled CCMV-CP (B3), His-CCMV (B4), CCMV-His (B5), His-CCMV-His (B6), NΔ24-CP (B7), His-NΔ24-CP (B8),
M2e(23)NΔ24-CP (B9), His-HA-NΔ24-CP (B10), HA-NΔ24-CP (B11), VP1-CP (B12), 2C-CP (B13), VP1-NΔ24-CP (B14), 2C-NΔ24-CP (B15), CP-HA (B16),
CP-M2e(23) (B17, B18).(c) Higher resolution of four selected CCMV particles including CCMV virion, CCMV-CP, NΔ24-CP and VP1-NΔ24-CP shown
on the top-right of each electron micrograph. Magnification 20,000x, scale bar represents 200 nm
Fig. 5 Schematic illustration of loop-inserted and coat protein fusion constructs expressed in E. coli. The ectodomain of M2e-protein of Influenza A virus:
M2e(23), M2e(15) and M2e(7) introduced within the predicted loops (βB-βC-M2e(23), βD-βE-M2e(23), βF-βG-M2e(23)/M2e(15)/M2e(7) and βH-βI-(23)/
M2e(15)/M2e(7) as adaptors via SpeI and SstI overhangs. Foot and mouth disease virus (VP1/2C) Influenza A virus epitopes [M2e(23) and HA] were fused by
PCR to the N-terminus of the CCMV-CP (VP1/2C-CP) and NΔ24-CP (VP1/2C/M2e/HA-NΔ24-CP), and C-terminal to CCMV-CP (CP-HA, CP-M2e)
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between 26.8 nm and 28.3 nm. Only those for CP-HA
and CP-M2e(23) on average were larger, i.e. 31.7 ±
3.6 nm respectively 32.7 ± 3.1 nm (Fig. 7).
Encapsulation of mRNA
Since the N-terminal domain of CCMV CP is positively
charged (Fig. 8a) and involved in the interaction and
encapsulation of (viral) RNA [19], the presence of (m)
RNA within CCMV CP-derived VLPs, through sequence
non-specific interactions, was anticipated. To test this,
VLPs from CCMV-CP chimera were subjected to a total
RNA purification protocol and the RNA collected ana-
lyzed by RT-PCR for the presence of RNA. Due to the
known sequence (bacterially synthesized) CCMV CP
transcripts were selected for amplification, using spe-
cific primers for the CP gene (Fig. 8b and Table 2).
VLPs derived from CCMV CP chimera that lacked the
first 24 aa (NΔ24-CP) were included. While the samples
of CCMV-CP, NΔ24-CP, VP1-CP, 2C-CP and CP-HA gave
a clear positive RT-PCR product of expected size, those
from VP1-NΔ24CP and 2C- NΔ24CP only gave a very
weak signal. PCR products from clear positive samples
were cloned and sequenced and confirmed the presence
of NΔ24CP/CCMV-CP mRNA in VLPs. In contrast,
no RNA was detected at all in VLP samples from
M2e(23)NΔ24-CP, HA-NΔ24-CP and CP-M2e (Fig. 8b).
To find out whether encapsulation of RNA could be
correlated to epitope sequences with a positive charge,
similar to the original N-terminus of CP, the charges of
the N-terminal domain from the CCMV CP-derived
chimera were calculated (see Materials and Methods) at
pH 7.4 and 4.8, corresponding to buffer conditions
reflecting the CCMV CP disassembly and CCMV VLP
reassembly steps. Only two out of eight proteins, i.e.
M2e(23)NΔ24-CP and HA-NΔ24-CP and from which
the VLPs did not encapsulate RNA, showed a negative
charge at pH 7.4, whereas all other proteins revealed a
range of positive charges. Furthermore, only M2e(23)NΔ24-
CP revealed negative charge at pH 4.8.
CCMV-derived VLPs containing Schmallenberg virus
peptide sequences
The analysis of CCMV-CP chimera indicated that the
extremities of the CCMV CP protein, or the N terminus
of a NΔ24-CP mutant could be exploited for epitope
fusions in light of subunit vaccine production, whilst
maintaining VLP formation. To further substantiate the
usefulness and rapid ease of exploitation of CCMV
VLPs for the production of potential subunit vaccines,
peptide sequences were selected based on a search for
Fig. 7 Size measurement of chimeric CCMV-CP/ NΔ24-CP VLPs. The average size of VLPs from CCMV-CP, NΔ24-CP, M2e(23)NΔ24-CP, VP1-CP,
VP1-NΔ24-CP, 2C-CP, 2C-NΔ24-CP, HA-NΔ24-CP, CP-HA and CP-M2e(23) are presented in comparison to the size of plant-purified CCMV virions
(See figure on previous page.)
Fig. 6 Expression of loop-inserted and terminal fusion CCMV constructs in E. coli. (a) SDS-PAGE analysis of cell extract (CE) and reassembled VLP pellet
(RP) from the M2e(23) loop-inserted CCMV-CP (A1) βB-βC-M2e(23), (A2) βD-βE-M2e(23), (A3) βF-βG-M2e(23) and (A4) βH-βI-M2e(23). (b) SDS-PAGE
analysis of M2e(7) and M2e(15) within βF-βG (B1,B3) and βH-βI(B2, B4) CCMV-CP loops. (c) SDS-PAGE (upper panel) and western blot (lower
panel) of βF-βG M2e(7)/M2e(15) and βH-βI M2e(7)/M2e(15) detected by monoclonal anti-His-tag and M2e sera, respectively. (d) Immunoblot
detection of VP1 and 2C fusions to CCMV-CP and NΔ24-CP using polyclonal anti-CCMV serum (D1) and serum from FMDV-infected guinea pig
(D2). Induced empty pET-28a and CCMV-CP were used as negative and positive control, respectively. (e) Detection of M2e fused to NΔ24CP
using polyclonal anti-CCMV (E1) and monoclonal anti-M2e (E2) sera. Molecular size marker is indicated on the left
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conserved sequences or epitope predictions, from the
GN and GC glycoproteins of the recently emerged
Schmallenberg orthobunyavirus and fused at the afore-
mentioned sites either singly or at both ends simultan-
eously (Fig. 9a). After expression and VLP formation, as
expected, VLPs were readily obtained for all chimera
designed (Fig. 9b).
Discussion
Nowadays numerous virus-like particles, due to their abil-
ity to support a strong natural immune response, are be-
ing exploited as scaffolds to produce peptide-based
vaccines. In this study we have demonstrated the potential
of CCMV VLPs as scaffold for foreign epitope presenta-
tion, and identified sites for peptide fusions without abol-
ishing VLP formation. While insertions of a 6xHis-tag and
M2e (varying in size from 7, 15 to 23 aa) into predicted
external loops βB- βC, βD-βE, βF-βG and βH-βI abolish
VLP formation, their fusions at the N- and/or C-
terminus of CCMV CP or the N-terminus of a mutant
lacking the first 24 N-terminal aa residues (NΔ24) still
maintain VLP formation. The possibility to further explore
these termini for epitope fusion has been supported by
VLP formation of CCMV CP chimera containing T- and B
cell epitopes from IAV (HA, M2e), and FMDV (2C, VP1).
The exploitation of the C-terminus, however, seems
limited since fusions of up to 8 aa (His and HA) did
not abolish VLP formation, while larger epitopes i.e.
M2e(23) gave rise to more amorphous and unstable
VLPs. All epitopes fused were detectable with the ex-
ception of those from CP-His and 2C-NΔ24-CP, which
may have been caused by protein misfolding or the epi-
tope sequence, e.g. in case of 2C, being trimmed in size
too much and thereby not being recognized anymore by
the antisera. The ease and speed at which additional
chimeric VLPs containing SBV epitopes at both termini of
CCMV CP have been made underscored the feasibility of
CCMV VLPs as scaffold for epitope presentation.
CCMV CP and derivatives expressed in E. coli consist-
ently ended up in the insoluble fraction. To circumvent
this problem and generate VLPs a protocol has been
established that involves a denaturation and resolubili-
zation step, prior to VLP reassembly and subsequent
purification by ultracentrifugation on a sucrose cush-
ion. In this way, all CCMV CP chimeras that contained
an N-terminal fusion up to 27 aa and ended up in a pellet
after sucrose cushion corresponded with the presence of
VLPs, with the exception of those containing a relatively
large C-terminal fusion. For the latter, the presence of a
(MMPC) pellet corresponded either with amorphous ag-
gregates or VLPs.
Abolishment of VLP formation from CCMV CP con-
taining insertions into the 4 selected loops, indicates that
these do not tolerate any insertion. Only two hydrophilic
Fig. 8 N-terminal charge of chimeric subunits from VLPs and detection of mRNAs. a N-terminal charges of CCMV-CP, NΔ24-CP, M2e(23)NΔ24-CP,
VP1-CP, VP1-NΔ24-CP, 2C-CP, 2C-NΔ24-CP, HA-NΔ24-CP, CP-HA and CP-M2e(23) were calculated at pH 7.2 and 4.8 for ≥24 and ≥45 N- terminal
residues using Protein Calculator version 3.3 (http://www.scripps.edu/~cdputnam/protcalc.html). b RT-PCR detection of mRNAs encoding CCMV coat
proteins. ⊕Positive charge derived from NH2 group. (+) indicates the presence of RNA followed by PCR product cloning and sequence confirmation
and (-) for its absence not being cloned and sequenced
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Table 2 Primer and adapter sequences used in this study

































His- NΔ24CP * GGGCCATGGGTCACCACCACCACCACCACACTCGTGTGGTCCAACC (F)
CCCAAGCTTCACTAATACACCGGAGTGAAAGAGTCGTCAAACGTAGGTCTGAC (R)
HA- NΔ24CP* GGGCCATGGGGTGGACCATTCTGAAACCGAACGATGCGATTAACTTTGAAAGCAACCCCGGGACTCGTGTGGTCCAACCTG (F)
CCCAAGCTTCACTAATACACCGGAGTGAAAGAGTCGTCAAACGTAGGTCTGAC (R)
His-HA- NΔ24CP* GGGCCATGGGGCACCACCACCACCACCACTGGACCATTCTGAAACCGAAC (F)
CCCAAGCTTCACTAATACACCGGAGTGAAAGAGTCGTCAAACGTAGGTCTGAC (R)
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loops from these, i.e. βB-βC and βF-βG, are predicted as
being exposed and potentially antigenic. While our data
did not identify loops that tolerated small epitope inser-
tions, previous work claimed a predicted surface loop in
which the insertion of an 11 aa peptide (referred to as
CPPep11) still maintained VLP formation. However, the
location of the loop has not been described to allow a
comparison to the data presented here [25].
Although no VLPs were generated when insertions
were made in any of the loops tested, only βF-βG still
supported formation of MMPCs when epitopes of varying
size were inserted (Fig. 4a1-4). The failure to correctly fold
into VLPs might be due to loss of the ability to switch
between the pentameric and hexameric conformations
of the chimeric CP. Earlier studies showed that forma-
tion of VLPs from Cowpea mosaic virus (a comovirus
with icosahedral particles) containing epitope insertions
in the loops (βC’-βC” and βE-αB) depended on both pI
value and size of the peptide [28]. In our case we consist-
ently observed more MMPC of CCMV βF-βG-M2e(15)
than βF-βG M2e(7) and βF-βG-M2e(23) (Fig. 4a1-4)
which likewise could indicate that, although VLPs were
not generated, composition and peptide size both influ-
ence the refolding status of CCMV CP. In bacterio-
phage Qβ, similar problems were encountered and only
by mixing wild-type subunits and chimeric subunits in
specific ratios chimeric VLPs were obtained [29]. The
latter were likely resulting from lowered sterical hin-
drances between the subunits that lead to an increased
interaction and subsequently supported formation of hy-
brid VLPs. In light of this, we applied a similar strategy to
generate VLPs from epitope insertions into loop βF-βG.
To this end, βF-βG-M2e(7) was mixed in two ratios
(1:1 and 2:1) with CCMV CP and subjected to VLP
reassembly. Preliminary data indicate that VLPs were
observed when both were mixed 2:1, but not when
mixed in equal ratios (unpublished observation). The
presence of the βF-βG-M2e(15) subunit in those VLPs
still has to be confirmed.
All N-terminal fusions to CCMV CP/NΔ24-CP, whether
His-tag or virus derived epitopes, resulted in the forma-
tion of VLPs indistinguishable from those of CCMV CP
and from CCMV virions, whereas those from fusions to
NΔ24 tended to be a bit more heterogeneous in size
(Fig. 4 and Fig. 7). The latter was earlier observed, but
more strongly with VLPs from a mutant NΔ34 mutant
expressed in P. pastoris [25]. Furthermore, comparison
of VLPs from His-CP and His-NΔ24-CP revealed less
staining in the core of VLPs from His-NΔ24-CP. It is
known that the N-terminal end of CCMV CP faces to the
interior of CCMV particles where it interacts with the
RNA genome. Fusion of epitopes at the N terminus thus
is likely not leading to a presentation on the surface of
VLPs. For this reason it was interesting to see whether re-
moval of most of the N terminal domain, without abolish-
ing VLP formation or leading to an amorphous VLP
suspension, would render relatively stable and
homogenous VLPs in which epitopes instead of being in-
ternalized would become exposed at the outside. However,
several attempts to immuno-gold localize M2e(23) on the
surface of NΔ24-CP derived VLPs failed.
During this investigation, the VP1 epitope (27 aa) so far
has been the largest fusion made at the N-terminus of wt
CCMV CP, without abolishing VLP formation. Consider-
ing that NΔ24-CP still rendered VLPs, this would suggest
that CCMV CP can be used as a scaffold for peptides at
least up to 51 aa, subject it is fused at the N-terminus of
NΔ24-CP.

















Restriction enzymes (BamHI, HindIII, NcoI, PstI, SpeI and SstI) and adaptor overhangs are shown in underlined letters.* Epitopes were PCR-fused to the CPs by two
rounds of PCR
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In contrast to all N-terminal fusions, CCMV CP chimera
containing C-terminal fusions (6xHis-tag, M2e(23) and
HA), especially large ones, ended up in more amorphous
and larger VLPs. Those from CP-HA revealed two add-
itional types of particles i.e. opened particles and integrated
ones, while preparations from CP-M2e showed to contain
Fig. 9 Schematic view and electron micrographs of Schmallenberg virus (SBV) Gn, Gc CCMV-based chimeras. a Location and sequence of CCMV
constructs harboring SBV glycoprotein peptides fused to N- and C-termini including N-terminal single fusions (a1–a4) and dual terminal fusions
(a5, a6). b Electron micrographs of chimeric CCMV VLPs co-expressing SBV epitopes as depicted in panel a (b1–b6)
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the largest particles among all chimeric VLPs from this
study (Fig. 7). The latter preparations also revealed unique
tubular-like particles. Whether these especially arise due to
ionization of carboxyl groups at low pH (5.3-5.7) con-
ditions, which affect the assembly and stability of the
particles [30], remains to be investigated. In light of this it
is interesting to note that after two weeks for most N-
terminal fusion CCMV CP constructs VLPs were still
stable, while no VLPs were observed anymore for CP-
M2e(23). It cannot be ruled out that, in addition to the
relatively large size of M2e(23), the presence of two in-
ternal cysteine residues in the epitope sequence has a
major influence on VLP formation and stability. Since the
N-terminus of CCMV CP is known to interact with the
viral RNA genome, the ability of the N-terminus (Fig. 8)
within VLPs from different CP-chimera to interact with
RNA, e.g. its own mRNA from the E. coli extract, was
analysed. Earlier, studies have shown that both mRNA
and host RNAs from P. fluorescencs are encapsulated in
CCMV CP VLPs [26]. Here, we observed that bacterially
synthesized CP-encoding RNA molecules were similarly
detected in VLPs from CCMV CP and CP chimera
containing N-terminal fusions of VP1 or 2C, but not in
those from M2eNΔ24-CP and HA-NΔ24-CP. Other
studies already indicated that VLP-formation is not trig-
gered by RNA/DNA molecules as a treatment with
RNaseA and DNase does not abolish the formation of
VLPs from CCMV CP [23, 26]. The lack of RNA from
the M2eNΔ24-CP and HA-NΔ24-CP derived VLPs is not
just due to the N terminal deletion, since VLPs from
NΔ24-CP still contained RNA. Instead, the lack of RNA is
likely caused by the M2e and HA sequences that provide
a negative charge under conditions of VLP reassembly
and thereby do not support encapsulation of RNA. This
is supported by other studies where VLPs lack RNA in
case the (positively charged) N-terminus of CCMV CP
is replaced for a negatively charged one [25]. Although
the presence of RNA in VLPs from NΔ24-CP, lacking
the basic residues from the first 24 aa, was unexpected
its remaining N-terminal sequence with neutral to some-
what positive charge still seemed sufficient to support
RNA encapsulation. Altogether, the data indicate that
epitope fusions at the N-terminus that provide a clear
negative charge prevent RNA from becoming encapsu-
lated. From VLPs harbouring a C-terminal fusion of M2e
or HA, only those from CP-HA contained RNA. Although
speculative, the absence of RNA from VLPs of CP-M2e
could be caused by instability of the (amorphous) VLPs,
allowing the RNA to become more accessible to nucleases
and leading to its degradation.
To ensure that CCMV VLPs, when used as scaffold for
epitope presentation or drug delivery nanoparticles, com-
ply with safety rules they should be free from nucleic
acids. Chimeric VLPs therefore have to be treated with
RNase A and DNase before reassembly [23, 26]. CCMV
particles have already been shown feasible for applications
in biotechnology such as the encapsulation of anionic
non-genomic polymers in CCMV VLPs lacking genomic
materials [31]. Recently also DNA origami structures
coated with CCMV capsid proteins were efficiently de-
livered into human cells [32], and viral coat proteins
shown to encapsulate gold nanoparticles [33].
While data presented in this study indicate that VLPs from
NΔ24-CP present one of the most interesting scaffolds for
epitope display, it is highly unlikely that very large sequences
can be fused to its N-terminus without disrupting VLP for-
mation. Recently another strategy has been developed [23]
that might circumvent this problem. During this strategy a
positively charged K-coil sequence (KIAALKE[3]) was fused
at the N-terminus of CCMV CP. Another, negatively charged
E-coil (EIAALEK[3]) sequence, able to heterodimerize to the
K-coil, was fused to eGFP. Mixing of K-coil-CP in a certain
ratio with CCMV CP subunits, enabled the encapsulation
of 15 E-coil-eGFP molecules during reassembly of
CCMV VLPs. Although this strategy allows encapsula-
tion of very large molecules, due to volume constraints
of the core, the number of these will be limited.
Whether (CCMV-derived) VLPs present the best and
most widely applicable nanoscaffolds for various purposes,
or others like DNA origami structures [34] turn out to
be more promising for these in the future remains to
be investigated.
Conclusions
In this study we have demonstrated the feasibility of
CCMV-based VLPs as scaffold for epitope presentation,
but limited to fusions of peptide sequences to the N
and/or C-terminus of CCMV CP or the N-terminus of
a mutant lacking the first 24 N-terminal aa residues (NΔ24).
Several CCMV CP chimeras have been constructed that
resulted in the formation of VLPs containing various
(neutralizing) viral epitopes from IAV (HA and M2e),
FMDV (VP1 and 2C) and SBV (GN and GC), although
their real potential in the application for vaccine pur-
poses still has to be demonstrated.
Recently, CCMV particles have been shown to be bio-
compatible after injection into mice (no observed levels
of toxicity and accumulation in specific organs), which
underlined their appropriateness and potential for med-
ical applications [24].
Methods
Plasmid DNA and cloning
CCMV CP was PCR amplified from a plasmid DNA tem-
plate (pFBD/CCMV-CP) using Phusion DNA polymerase
(Promega) and a primer set to introduce NcoI and HindIII
restriction sites for feasible cloning purposes. Based on the
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crystal structure of the CCMV CP subunit [19], four differ-
ent loops were selected to be tested as potential sites for
epitope insertion. Insertion of a 6xHis-tag into the pre-
dicted loops, including βB-βC, βD-βE, βF-βG and βH-βI
(Fig. 1), was performed using PCR mediated mutagenesis,
to introduce SpeI and SstI restriction sites, and subsequent
cloning of a His-tag adaptor into the loops. Constructs
containing terminal-end fusions with a His-tag were engi-
neered using a two-step PCR (Fig. 2) during which se-
quences for the NcoI and HindIII restriction sites and the
6xHis-tag were provided by the primers (Table 2). Since
IAV in human and FMDV in livestocks both cause eco-
nomically important diseases [35, 36], totally 4 genuine
epitopes have been selected. The sequence for the ecto-
domain of non-glycosylated membrane protein M2 (M2e:
SLLTEVETPTRNGWECRCSDSSD) a highly conserved
epitope across all influenza A isolates, used for terminal fu-
sions within CCMV CP, was selected based on a consensus
amino acid sequence of M2e [37]. M2e has been shown
100 % protection in vaccinated animals against influenza
strain H1N1 [13]. For the insertion of size variants of the
M2e epitope into the loops of CCMV CP, adapters were
designed coding for shorter versions of M2e containing 7
(SLLTEVE) or 15 (SLLTEVETPTRNGWE) aa residues and
cloned into the loops. An N-terminal CP mutant, lacking
first 24 amino acid residues NΔ24, was generated to abol-
ish interaction with non-cognate host RNA and improve
chances of obtaining RNA-free VLPs. To generate an M2e
fusion to NΔ24-CP, the sequence was subcloned from
pDONR201M2eNΔ24-CP via NcoI and HindIII restriction
sites (Fig. 2). A T-cell activating epitope of H5N1 subtype
in chickens i.e. HA (aa residues 246-260 WTILKPNDAIN-
FESN) was selected from strain A/Hong Kong/156/97.
This epitope has a potential use in generation of vaccine in
chickens [38]. Additionally two epitopes were selected
from FMDV serotype O, the most prevalent serotype
worldwide [39]; the first one presenting a B/T-cell epitope
from the structural VP1 protein (aa residues 136-160,
YGDTSTNNVRGDLQVLAQKAERTLPGS, genbank ac-
cession no. CAC22206) [40, 41] and the second one a T-
cell epitope from the nonstructural 2C protein (aa residues
68-76, EWLDNARQAGSTR, accession no. AJ539137)
[42]. Epitope sequences of HA, VP1, 2C and M2e were
PCR-fused to the N or C-terminus of CP (Fig. 5) and
cloned into the pET28a (Novagen) expression vector. The
integrity of constructs was verified by DNA sequencing.
The sequence of all primers and adapters used for the
construction of CCMV CP chimera are listed in Table 2.
Recombinant CCMV CP expression in E. coli
Constructs were transformed into E. coli BL21 (DE3). A
100 ml culture containing 50 mg/l kanamycin was freshly
inoculated with 1 ml of the overnight culture and grown
at 37 °C until an OD600 of 0.6 was obtained. Bacteria were
induced for protein expression with 0.25 mM IPTG and
incubated at 37 °C for another 4 hours. Then, cells were
pelleted by centrifugation at 5000 rpm for 15 minutes at
4 °C and stored at -20 °C until further analysis.
In vitro disassembly and reassembly of CCMV CP to VLPs
CCMV VLPs were re-assembled from insoluble CP ag-
gregates collected from E. coli lysates. To this end, a
disassembly-reassembly process was carried out entirely
at 4 °C, as follows: E. coli cells induced and incubated
overnight were pelleted and resuspended in 5 ml of
disassembly buffer (0.020 M Tris-HCl, 0.9 M NaCl,
0.001 M DTT pH 7.4). Next, cells were lysed by con-
tinuous ultra-sonication (Sonics Vibra Cell, CT., USA)
during 3 rounds of 1 min at 40 % amplitude (output 6).
The lysate was centrifuged at 5.000 rpm for 15 min and
the insoluble fraction resuspended in 10 ml of disassembly
buffer containing 8 M urea and again sonicated but this
time at 20 % amplitude using pulses of 10 seconds until
the pellet was entirely dissolved. Thereafter another 15 ml
of disassembly buffer was added and mixed with the
sonication liquid, the sample was centrifuged at 15,000 rpm
for 15 min. The supernatant was collected and dialyzed 6
times against dialysis buffer (0.01 M Tris-HCl pH7.4). The
soluble CCMV CP fraction was finally reassembled into
VLPs during 2 dialysis steps against reassembly buffer
(0.1 M NaAc, 0.9 M NaCl, 0.010 M MgCl2 pH 4.8) and
concentrated by ultracentrifugation (Beckman) on a 30 %
sucrose cushion at 40,000 rpm for 3 hours. The pellet
was resuspended in 1-2 ml of virus buffer (0.1 M NaAc,
0.001 M EDTA, pH 4.8) and stored at 4 °C until further
analysis.
SDS-PAGE and immunoblot analysis
Bacterial cell lysates containing expressed (chimeric) CCMV
CP protein or samples of purified VLPs were resolved
onto a 15 % SDS-PAGE gel. Proteins were transferred
onto Immobilon P membrane (Millipore Corp., MA, USA)
and screened with anti-CCMV polyclonal crude antiserum
(1:1000), anti-His (1:1000) and anti-M2e monoclonal
antisera (1:1000 of a 1 mg/ml stock; Abcam Inc., Cambridge,
MA). For VP1 and 2C epitopes, a serum from FMDV-
infected guinea peg (kindly provided by Dr. A. Dekker,
Central Veterinary Institute, Lelystad, the Netherlands)
was used (1:500 crude serum).
EM and immuno-electron microscopy
The reassembly of all CCMV CP proteins into VLPs was
verified by transmission electron microscopy. To this
end, protein samples collected after in vitro reassembly
and sucrose cushion were diluted 10x in virus buffer
and 10 μl placed on 400 mesh copper grids (AURION,
Wageningen, The Netherlands) for 2 min followed by
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negative staining. For immuno-electron microscopy [43]
10 μl of the samples was placed on 400 mesh nickel grids
(AURION) for 5 min and followed by blocking using virus
buffer containing 1 % BSA for 20 min. Polyclonal (anti-
CCMV) and monoclonal (anti-His and anti-M2e) antisera
were used (1:1000) as primary antibodies and goat-anti-
rabbit- and anti-mouse-gold (9 nm) conjugates (AURION)
used at a 1:20 dilution in virus buffer (supplemented with
1 % BSA) as secondary antibodies. After 6 washing steps,
samples on the grids were fixed using virus buffer con-
taining 1 % glutaraldehyde. The preparations were nega-
tively stained with 2 % Uranyl acetate (pH 3.7) for 1 min
and dried at room temperature. The grids were examined
with a JEOL JEM-1011 transmission electron microscope
using wild type CCMV CP derived VLPs as a positive
control.
Detection of RNA in purified VLPs
A major safety issue related to the exploitation of VLP-
based systems for vaccine purposes deals with the presence/
absence of genetic material within VLPs. To analyze the
presence of mRNA transcribed from the pET-28-CCMV
CP-chimera plasmids and encapsulated in VLPs, 200 μl
purified VLP suspensions from CCMV CP, NΔ24-CP,
M2e(23)NΔ24-CP, HA-NΔ24-CP, VP1-NΔ24-CP, 2C-
NΔ24-CP, VP1-CP, 2C-CP, CP-HA and CP-M2e(23) was
subjected to a total RNA isolation protocol using Trizol
according to the manufacturer’s instructions (Invitrogen).
As a negative control, a sample of IPTG-induced BL21
cells containing empty pET-28 plasmid DNA was included.
To detect CCMV-CP-specific RNA molecules transcribed
from pET28, RT-PCR was performed on total RNA puri-
fied from VLPs using specific primer sets (Table 2).
Charges of CP and CP-chimera were calculated using
Protein Calculator v3.3, (C. Putnam, The Scripps Research
Institute, USA) at pH 7.4 and 4.8, corresponding to buffer
conditions reflecting the CCMV CP disassembly and
CCMV VLP reassembly steps as described above.
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